About M-Life™
Creating a Virtual Representation of the Human Body
M-Life™ Uses Novel Algorithms to Identify Unique Atom Interactions within a Molecule Utilizing Deep Learning, Artificial Intelligence and Big/Small Data
The M-Life™ process begins with data-fusion wherein both quantitative and non-quantitative data associated with efficacy and adverse effects are fused. Molecular structures are transcribed to an energy-density analog. Algorithmic assessment is accomplished via M-Life’s P2L™ (Pattern-to-Lead) platform. MiST™ aggregate’s all molecular modalities (the independent pattern’s associated efficacy and toxicity), building a composited representation of attributes similar to image tomography.
Our discovery process differs from traditional target based discovery. M-Life™ integrates both target based discovery with phenotypical based discovery. And unlike the serial process of evaluating ADME, toxicity and other desired properties, our platforms integrate all of these desirable and undesirable properties into a comprehensive virtual assessment.
MiST™ and P2L™ are proprietary to M-Life™, serving as the basis for ‘Repurposing of Existing Drugs on Market’, ‘Selection of High Value Asset Molecules’ and/or the ‘Design of Novel Molecules’ in a directed fashion.
From Platform Validation to Multiple Programs in Three Years
Roll-out from Company Formation to Today
How did we validate our platforms? We began by separating biological and molecular system complexities. The design of novel fluorescent molecules (fluorophores) were chosen for this purpose. The end result is a new class of Sulphur-Selenium based dyes and a simple heuristic to guide the design of additional fluorophores. M-Life™ then expanded platform validation to include biological effects by identifying existing drugs on market that could be repurposed to treat COVID-19. The Company released four press releases covering the results of these efforts, including possible drugs aimed at viral replication as well as cytokine storm. Additionally, the toxicological effects and plausible scaffolds for the design of new drugs were presented.
M-Life™ now has 14 design programs. The most advanced of these programs, oncology Multi-Targeting Agents (MTA’s), are now in preclinical testing. For more information see about our present cancer drug focus as well as our other programs, see the Technology page.